SEC Form 4 · accession 0001669866-26-000010
Dianthus Therapeutics, Inc. /DE/ · DNTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marino Garcia
Officer — CEO AND PRESIDENT · Director
Period of report
Aug 7, 2026
Accepted (ET)
Aug 7, 2026 · 6:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001690585
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 7, 2026 | M | 40,000 | $8.44 | A | 105,292 | D | |
| Common Stock | Aug 7, 2026 | M | 126,000 | $8.44 | A | 231,292 | D | |
| Common StockF2 | Aug 7, 2026 | S | 10,384 | $107.49 | D | 220,908 | D | |
| Common StockF3 | Aug 7, 2026 | S | 23,907 | $108.05 | D | 197,001 | D | |
| Common StockF4 | Aug 7, 2026 | S | 2,373 | $109.10 | D | 194,628 | D | |
| Common StockF5 | Aug 7, 2026 | S | 2,536 | $110.02 | D | 192,092 | D | |
| Common Stock | Aug 7, 2026 | S | 800 | $110.76 | D | 191,292 | D | |
| Common StockF6 | Aug 7, 2026 | S | 104,091 | $107.96 | D | 87,102 | D | |
| Common StockF7 | Aug 7, 2026 | S | 21,909 | $108.72 | D | 65,292 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F8 | $8.44 | Aug 7, 2026 | M | 40,000 | D | — | Jun 6, 2032 | Common Stock | 40,000 | 286,004 | D |
| Stock Option (Right to Buy)F8 | $8.44 | Aug 7, 2026 | M | 126,000 | D | — | Jun 6, 2032 | Common Stock | 126,000 | 160,004 | D |
Explanation of responses
- F1The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2026.
- F2The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.68 to $107.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.68 to $108.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.74 to $109.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $109.75 to $110.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.52 to $108.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- F7The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.57 to $108.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F8The shares of common stock underlying this stock option award vested as to 25% of the shares on November 1, 2022, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.